相关实验视频
Updated: Jan 18, 2026

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
909
针对成年人群中的肥胖及其并发症的多学科治疗:叙述性审查
Ana Raimunda Dâmaso1,2,3, Flávia Campos Corgosinho4,5, Deborah Cristina Landi Masquio1,6
1Post-Graduate Program of Nutrition, Federal University of São Paulo - Paulista Medicine School - UNIFESP-EPM, São Paulo, Brazil.
概括
针对肥胖的多学科治疗,包括运动,营养和行为咨询,有效地管理并发症. 这种整体方法改善了健康结果,并降低了与肥胖相关的风险.
科学领域:
- 肥胖医学 肥胖医学
- 代谢障碍 代谢障碍 代谢障碍
- 公共卫生 公共卫生
背景情况:
- 肥胖是一种复杂的慢性疾病,需要全面的管理.
- 生活方式干预是基本的,但对于成年人来说,单独干预往往是不够的.
- 相关的并发症显著影响患者健康和医疗保健系统.
研究的目的:
- 审查多学科治疗在治疗肥胖及其并发症方面的有效性.
- 在多学科框架内综合各种治疗方式的证据.
- 突出全面,以团队为基础的方法对肥胖护理的重要性.
主要方法:
- 成年人群临床研究的叙述性综述.
- 包括各种多学科干预措施 (短期和长期).
- 从初级和中等保健机构的研究分析.
主要成果:
- 多学科治疗在控制与肥胖相关的不良影响方面显示出显著的益处.
- 观察到的改善包括减少炎症生物标志物和心脏代谢风险因素.
- 在诸如失脂症,糖尿病,高血压和NAFLD等疾病中发现了积极的影响.
结论:
- 一个整体的,多学科的团队方法对于有效的肥胖管理至关重要.
- 综合性干预可以减轻许多与肥胖有关的健康问题.
- 针对肥胖症全面改善患者的治疗结果和生活质量.
相关概念视频
Diabetes: Management and Pharmacotherapy
868
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
868
Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Binge Eating Disorders
426
Binge eating disorder is a significant mental health condition characterized by recurrent episodes of excessive food consumption within a short period, accompanied by a perceived loss of control over eating behavior. Unlike occasional overeating, binge eating disorder is marked by distressing emotions such as guilt, shame, and anxiety following binge episodes. The disorder affects individuals across different ages and backgrounds, with profound implications for physical and psychological...
426
Acute Coronary Syndrome IV: Interprofessional Care
220
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
220
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
248
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
248
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
169
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
169

